Zheng Quan Shi Bao Wang·2026-01-02 09:35Group 1 - The company, Innovent Biologics, announced significant progress in clinical research for its novel TYK2 inhibitor soficitinib, with the completion of patient enrollment for a Phase III registration clinical trial for moderate to severe atopic dermatitis (AD) [1] - The Phase III trial for AD included 579 patients, while the Phase II trial for vitiligo enrolled 162 patients, both trials being randomized, double-blind, and placebo-controlled [1] - Soficitinib is a highly selective oral TYK2 inhibitor developed by the company, targeting various T-cell related autoimmune diseases, with a focus on dermatological conditions such as atopic dermatitis and vitiligo [1] Group 2 - According to WHO, there are approximately 230 million people globally suffering from atopic dermatitis, making it the most burdensome non-fatal skin disease, with nearly 70 million patients in China [2] - The Phase II clinical study of soficitinib for moderate to severe atopic dermatitis achieved multiple efficacy endpoints, demonstrating superior efficacy and safety compared to other treatment modalities [2] - Vitiligo affects around 70 million people globally, characterized by the destruction of skin melanocytes, requiring long-term treatment to control lesion progression and promote repigmentation [2] Group 3 - The CEO of Innovent Biologics emphasized the significant unmet clinical needs for both atopic dermatitis and vitiligo, expressing optimism about the progress of soficitinib in addressing these chronic diseases [2]